NEUROKINE PHARMACEUTICALS INC. - Statements of Cash Flows (USD $)	12 Months Ended		128 Months Ended
	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
Cash flows from Operating Activities
Net Income (loss)	$ 341,425	$ 1,417,734	$ (2,160,372)
Accretion of discount on convertible debentures	95,759	96,531	202,988
Amortization	455	455	948
Loss (gain) on change in fair value of derivative liabilities	(550,419)	(2,244,910)	72,695
Shares issued for royalties			500,000
Shares issued for services		351,519	449,919
Stock-based compensation		14,676	61,911
Changes in operating assets and liabilities:
Amounts receivable, increase decrease	(4,254)		(4,254)
Accounts payable and accrued liabilities, increase decrease	34,357	82,477	134,442
Due to related parties, increase decrease	51,091	145,672	214,032
Net cash used in operating activities	(31,586)	(135,846)	(527,691)
Cash Flows from Investing Activities
Purchase of property and equipment			(2,276)
Net cash used in investing activities			(2,276)
Cash Flows From Financing Activities
Proceeds from loan payable	30,000	235,000	270,000
Repayment of loan payable		(150,000)	(150,000)
Proceeds from issuance of convertible debentures		37,870	102,949
Proceeds from issuance of shares			307,493
Net cash provided by financing activities	30,000	122,870	530,442
INCREASE (DECREASE) IN CASH	(1,586)	(12,976)	475
CASH, BEGINNING OF PERIOD	2,061	15,037
CASH, END OF PERIOD	475	2,061	475
Supplemental disclosures:
Interest paid		9,000	76,078
Income tax paid
Non-cash investing and financing activities:
Forgiveness of related party debt	7,500		7,500
Shares issued for conversion of debentures, shares		43,736	43,736
Shares issued for settlement of debt			10,000
Fair value of options and warrants exercised			$ 5,175